Acute Ischemic Stroke Market Anticipates Impressive Growth Trajectory Through 2032 - Asserts DelveInsight | Roche, Acticor, Revalesio, aptaTargets, Athersys, Bayer, Biogen, Bristol-Myers Squibb, Clinuvel, DiaMedica, Genentech, GNT Pharma, Janssen

The Acute Ischemic Stroke market is undergoing rapid evolution, driven by advancements in pharmaceutical and biotechnological research. With an increasing focus on innovative therapies and targeted interventions, companies are striving to address unmet medical needs and improve patient outcomes. This evolution is characterized by heightened competition, expanded clinical pipelines, and a growing emphasis on precision medicine approaches tailored to individual patient profiles.

DelveInsight's "Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Ischemic Stroke Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Acute Ischemic Stroke therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Ischemic Stroke treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Acute Ischemic Stroke: An Overview
According to the Centers for Disease Control and Prevention (CDC), a stroke happens when a blood vessel that supplies the brain with oxygen and nutrients becomes clogged by a clot or bursts (or ruptures). Brain cells die when they are deprived of the blood (and oxygen) required.

Symptoms of stroke depend on the severity and location of the stroke in the brain. Sudden onset numbness or weakness in an arm or leg, facial droop, difficulties speaking or comprehending speech, disorientation, issues with balance or coordination, and loss of vision are all indications of acute ischemic stroke. Stroke severity may be stratified based on NIHSS scores: very severe: >25; severe: 15-24; mild to moderately severe: 5-14; mild: 1-5. Various risk factors may increase the susceptibility to stroke. It includes high blood pressure, advanced age, high cholesterol, atrial fibrillation, sickle cell anemia, smoking, atherosclerosis, clotting disorders, and congenital heart defects.

Critical care specialists are important in the multidisciplinary approach used to treat AIS. Antiplatelet medication is the mainstay of care for treating stroke and transient ischemic episodes. Due to its affordability, accessibility, and relative safety, aspirin is the most extensively used medication.

Get a Detailed Overview of the Evolving Acute Ischemic Stroke Market Trends @
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Ischemic Stroke Market Key Facts
• In the 7MM, the Acute Ischemic Stroke Market size was found to be USD 1,300 million in 2022. The market is expected to grow by 2032, driven by rising incidence, better diagnosis, improved stroke care, and the launch of novel therapies.
• The United States accounted for the largest market share (>USD 700 million) of acute ischemic stroke in 2022 because the most advanced healthcare system is providing better patient access to therapies.
• The total EU4 (Germany, France, Italy, and Spain) and the UK market size of acute ischemic stroke were more than USD 300 million in 2022.
• Invimestrocel (Athersys/Healios) is expected to be the most successful therapy amongst the pipeline candidates and shall account for the highest market revenue in the coming years.
• Among the 7MM, the US accounted for the highest number of cases of acute ischemic stroke, with more than 700,000 cases in 2022, owing to the long-term psychological, physical, and social consequences among the population.
• Among the EU4 and the UK, Germany accounted for the highest number of acute ischemic stroke cases (around 250,000). On the contrary, Spain accounted for the least cases in 2022.
• The FDA has approved the standard gold therapy, tissue plasminogen activator, r-tPA, often known as alteplase, to treat ischemic stroke. Further, in November 2020, the US FDA approved BRILINTA to reduce the risk of stroke in patients with an acute ischemic stroke
• Several companies are working actively on new therapies expected to bring significant change in the acute ischemic stroke market. Some of the treatments that are in the late stage of development include glenzocimab (Acticor Biotech), DM199 (DiaMedica Therapeutics), LT3001 (Lumosa Therapeutics), nerinetide (NoNO Inc.), BMS-986177/milvexian (Bristol Myers Squibb Company/Janssen Pharmaceuticals), and invimestrocel (Healios/Athersys).

Acute Ischemic Stroke Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Ischemic Stroke therapies in the market. It also provides a detailed assessment of the Acute Ischemic Stroke market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Acute Ischemic Stroke drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Acute Ischemic Stroke Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Ischemic Stroke Epidemiology
The epidemiology section covers detailed insights into the historical, and current Acute Ischemic Stroke patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Acute Ischemic Stroke Epidemiology Segmented as -
• Total Incident Cases of Acute Ischemic Stroke
• Gender-specific Cases of Acute Ischemic Stroke
• Age-specific Cases of Acute Ischemic Stroke
• Type-specific Cases of Acute Ischemic Stroke

Get Key Insights Into the Evolving Acute Ischemic Stroke Epidemiology Trends @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Ischemic Stroke Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Ischemic Stroke market or expected to be launched during the study period. The analysis covers the market share by Acute Ischemic Stroke drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Acute Ischemic Stroke Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Acute Ischemic Stroke Market @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Acute Ischemic Stroke Therapeutics Assessment
The FDA has approved the standard gold therapy, tissue plasminogen activator, r-tPA, often known as alteplase, to treat ischemic stroke. Further, in November 2020, the US FDA approved BRILINTA to reduce the risk of stroke in patients with an acute ischemic stroke

Many molecules are in the pipeline to treat AIS patients across many countries to cater to their needs. Numerous prominent pharmaceutical and biotechnology enterprises are actively engaged in the advancement of therapies for Acute Ischemic Stroke. Some major late-stage products likely to hit the market during our study period 2019-2032 include MultiStem Cell Therapy (invimestrocel), Glenzocimab (ACT017), DM199, Nerinetide, and others.

At present, GNT Pharma stands at the forefront of this endeavor, boasting the most advanced stage of clinical development for its promising drug candidates targeting Acute Ischemic Stroke.

Leading Companies in the Acute Ischemic Stroke Therapeutics Market Include
Some of the key companies in the Acute Ischemic Stroke Therapeutics Market include AbbVie, Acticor Biotech, Angde Biotech Pharmaceutical, aptaTargets, Athersys|Healios K.K., Bayer, Biogen Inc., Bristol-Myers Squibb, Clinuvel Pharmaceuticals, DiaMedica Therapeutics, Genentech, Inc., GNT Pharma, Healios, Janssen Pharmaceutical, JCR Pharmaceuticals, Lumosa Therapeutics, NC Medical Research, NoNO Inc., NuvOx Pharma, Pharmazz, Pharming Group, PT. Prodia Stem Cell Indonesia, Revalesio Corporation, Roche, Shin Poong Pharmaceutical, Shionogi & Co., Ltd., Silver Creek Pharmaceuticals, Supergene, Tasly Pharmaceutical, TrueBinding, Inc, ZZ Biotech, and many more.

Emerging and Marketed Acute Ischemic Stroke Therapies Covered in the Report Include
• Nelonemdaz: GNT Pharma
• Tenecteplase: Genentech
• SP-8203: Shin Poong Pharmaceutical
• NONO-SC: NoNO Inc.
• Glenzocimab: Acticor Biotech
• DM199: DiaMedica Therapeutics
• LT3001: Lumosa Therapeutics
• Nerinetide: NoNO Inc.
• BMS-986177/milvexian: Bristol Myers Squibb Company/Janssen Pharmaceuticals
• Invimestrocel (Healios/Athersys
And Many More

Learn More About the Emerging Therapies and key Companies in the Acute Ischemic Stroke Therapeutics Market @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Ischemic Stroke Competitive Intelligence Analysis
4. Acute Ischemic Stroke Market Overview at a Glance
5. Acute Ischemic Stroke Background and Overview
6. Acute Ischemic Stroke Patient Journey
7. Acute Ischemic Stroke Epidemiology and Patient Population
8. Acute Ischemic Stroke Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Ischemic Stroke Unmet Needs
10. Key Endpoints of Acute Ischemic Stroke Treatment
11. Acute Ischemic Stroke Marketed Products
12. Acute Ischemic Stroke Emerging Therapies
13. Acute Ischemic Stroke Seven Major Market Analysis
14. Attribute Analysis
15. Acute Ischemic Stroke Market Outlook (7 major markets)
16. Acute Ischemic Stroke Access and Reimbursement Overview
17. KOL Views on the Acute Ischemic Stroke Market.
18. Acute Ischemic Stroke Market Drivers
19. Acute Ischemic Stroke Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.